Looking for antihypertensive mechanisms beyond ACE inhibition, we assessed 21 whether lactoferrin (LF)-derived peptides can act as receptor blockers to inhibit 22 vasoconstriction induced by angiotensin II or endothelin-1. The lactoferricinB (LfcinB)-derived 23 peptide LfcinB20-25 (RRWQWR), the low molecular weight LF hydrolysate (LFH<3 kDa), and two 24 peptides identified in LFH<3 kDa (LIWKL and RPYL) were tested in ex vivo assays of vasoactive 25 responses. The peptide RPYL was tested in radioligand receptor binding assays. Both LFH<3 26 kDa and individual peptides inhibited angiotensin II-induced vasoconstriction. RPYL showed 27 the highest ex vivo inhibitory effect and also inhibited binding of [ 125 I]-(Sar 1 , Ile 8 )-Angiotensin II 28 to AT1 receptors. By contrast, neither LFH<3kDa nor RPYL inhibited endothelin-1 and 29 depolarization-induced vasoconstrictions. In conclusion, LF-derived peptides selectively inhibit 30 angiotensin II-induced vasoconstriction by blocking angiotensin AT1 receptors. Therefore, 31 inhibition of angiotensin II-induced vasocontriction is suggested as a mechanism contributing 32 along with ACE inhibition to the antihypertensive effect of some LF-derived peptides. 33 34 KEYWORDS: bovine lactoferrin hydrolysate, lactoferrin-derived peptides, antihypertensive 35 mechanism, renin-angiotensin system, angiotensin-converting enzyme inhibition, angiotensin 36 receptor blocker 37
INTRODUCTION 38
Hypertension is probably the most important modifiable risk factor for cardiovascular 39 disease, and its management includes not only pharmacological treatment but also life-style 40 changes including physical activity and dietary habits. 1 The increasing perception about the 41 relation between food and health is fostering the development of functional foods providing 42 health benefits beyond basic nutrition. 2 Some food proteins contain embedded peptides that 43 once released behave as bioactive peptides with different health promoting properties 44 including blood pressure lowering effects. 3 45 The renin angiotensin system (RAS) is one of the main targets for the treatment of 46 hypertension. Its inhibition at three possible levels, angiotensin-converting enzyme (ACE), 47 upstream renin activity or downstream angiotensin receptors, is the pharmacological basis for 48 commonly used antihypertensive drugs. 4 ACE inhibition is also the most aimed target for 49 antihypertensive food-derived peptides developed as an alternative to drugs. 5 Although 50 different animal and plant proteins have been used, milk is the main source of 51 antihypertensive ACE-inhibitory peptides reported to date. 6 
52
In contrast to casein, there was much less information about the potential of milk 53 whey proteins as sources of antihypertensive peptides when some years ago we focused on 54 whey protein lactoferrin (LF) 7 and its well-known functional domain lactoferricin B (LfcinB). 8 55 First, we have shown that a set of peptides derived from LfcinB had inhibitory effects on in 56 vitro ACE activity and ex vivo angiotensin I-induced ACE-dependent vasoconstriction, 9 and 57 were orally effective antihypertensive peptides in spontaneously hypertensive rats (SHRs). 10 58
With regard to the parent protein, we have reported the inhibitory effects of a LF pepsin 59 hydrolysate (LFH) on ACE activity and ACE-dependent vasoconstriction. 11 Then, we have 60 recently described that the ultrafiltered hydrolysate (LFH<3 kDa) showed increased inhibitory 61 effect on ACE activity and orally antihypertensive effect in SHRs after both acute 12 and 62 chronic 13 administration. Finally, we have isolated and identified novel non-LfcinB-derived 63 4 peptides with ACE-inhibitory and antihypertensive properties, which could contribute to the 64 antihypertensive effects of LFH<3 kDa. 12 
65
The search for in vitro ACE inhibition is the most common strategy in the selection of 66 potential antihypertensive peptides derived from food proteins. However, it is difficult to 67 establish a direct relationship between ACE-inhibitory effect in vitro and antihypertensive 68 effect in vivo. On one hand, the in vitro ACE-inhibitory potency of food-derived peptides is 69 around 1000 times lower than that of ACE-inhibitory drugs like captopril, but there are no 70 substantial differences when their antihypertensive effects are compared. 14 On the other 71 hand, there is no correlation between in vitro and in vivo effects when different individual 72 peptides or protein hydrolysates are compared. To explain these apparent discrepancies one 73 should take into account both bioavailability issues and mechanisms of action other than ACE 74 inhibition when bioactive peptides are assayed in vivo. 15 Alternative antihypertensive 75 mechanisms reported for food-derived bioactive peptides include short-term vasoactive 76 mechanisms as well as long-term antioxidant and anti-inflammatory mechanisms. 16 
77
Looking for antihypertensive mechanisms beyond ACE inhibition in milk protein 78 derived bioactive peptides, we have shown that some LfcinB-derived peptides were dual 79 vasopeptidase inhibitors. In addition to ACE, they inhibit endothelin-converting enzyme (ECE), 80 a key enzyme of the endothelin system also involved in vascular tone and blood pressure 81 regulation. 17 We have also reported that orally effective antihypertensive LF hydrolysates may 82 act as dual vasopeptidase (ACE/ECE) or as single ECE inhibitors with different 83 antivasoconstrictor effects depending on the protease used to release bioactive peptides. 18 In 84 the present study, we aimed to assess whether LF derived peptides, in addition to inhibit the 85 converting enzymes of the angiotensin and endothelin systems, can act as receptor blockers to 86 inhibit vasoconstriction induced by angiotensin II or endothelin-1. For this purpose, we 87 included in the study the LfcinB-derived peptide LfcinB20-25 (RRWQWR), the low molecular 88 5 weight LF pepsin hydrolysate LFH<3 kDa, and two peptides identified in LFH<3 kDa (LIWKL and 89 RPYL), all of them with proven antihypertensive effects in SHRs. 90 effects. Actual peptide purities of supplied batches were 99.8% for LfcinB20-25, 97.7% for LIWKL 107 and 99.5% for RPYL. Stock solutions of each peptide were prepared at 5 mM concentration in 108
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MATERIALS AND METHODS
MilliQ water (Millipore Corp., Bedford, MA) and stored at 20°C. LfcinB20-25 (RRWQWR) and 109 LIWKL concentrations were determined on the basis of the extinction coefficient of W residues 110 by measuring the absorbance at 280 nm ( 280 = 5600 M 1 cm 1 for W residue), while RPYL 111 concentration was based on the dry weight of the peptide. 112 6 A low molecular weight fraction of an LF hydrolysate obtained by enzymatic treatment 113 with pepsin (LFH<3 kDa) was prepared as described previously, 11,12 and the resulting permeate 114 was freeze-dried and kept at room temperature until use. LFH<3 kDa was subjected to 115 determination of protein content by the bicinchoninic acid method (BCA; Sigma-Aldrich 116 Química) using BSA as standard and to in vitro assay of ACE-inhibitory potency (IC50) using the 117 method described by Sentandreu and Toldrá 19 as previously reported. 12 
Ex Vivo Functional Assays of Vasoactive Responses 148
The arterial segments were mounted in an organ bath containing Ringer-Locke solution 149
(120 mM NaCl, 5.4 mM KCl, 2.2 mM CaCl2, 1.0 mM MgCl2, 25 mM NaHCO3, and 5.6 mM 150 glucose) for computer-assisted isometric tension recording, as described previously. 9 The 151 contractile capacity of every arterial segment was checked by exposure to 50 mM KCl Ringer-152
Locke solution (NaCl replaced with an equimolar amount of KCl). Carotid arteries contracting 153 less than 1 g were discarded. 154
To assess effects on angiotensin receptor-mediated vasoconstriction, every arterial 155 segment was challenged with angiotensin II (1 µM). After washing out, each arterial segment 156 was subjected to one of the following protocols: (i) control, a second challenge to angiotensin 157 II to check for response reproducibility or (ii) treated, preincubation (20 min) with LFH<3 kDa 158 
Lactoferrin-Derived Peptides Do Not Inhibit Endothelin-1 and Depolarization-Induced 235
Vasoconstrictions 236
Endothelin-1 (10 nM) induced slow contraction ( Figure 4A ) with maximum effect 237 amounting to 108 ± 5 % relative to previous response to KCl, reached at 67 ± 6 min, with mean 238 slope of 61 ± 7 mg/min (n = 16). The effects of the different treatments on endothelin-1-239 induced vasoconstriction were assessed as shown for LFH<3 kDa in the representative 240 11 recording of Figure 4B . LFH<3 kDa (100 µg/mL), the peptide RPYL (20 µM) or valsartan (0.1 µM) 241 did not induce significant modification of the contractile response to endothelin-1 (Table 1) . 242
Finally, the effects of some treatments inhibiting angiotensin II-induced 243 vasoconstriction were assayed also against KCl-induced vasoconstriction. In control conditions, 244 the second vasoconstriction to KCl-induced depolarization was 116 ± 2 % of the first response 245 in the same arterial segment (n = 19), and the responses to KCl were not significantly different 246 after incubation with LFH<3 kDa (100 µg/mL), RPYL (20 µM) or valsartan (0.1 µM) ( Table 1) . 247 248 DISCUSSION 249 We have found that some lactoferrin (LF)-derived antihypertensive peptides inhibit 250 angiotensin II-induced vasoconstriction due to their blocking effect on angiotensin AT1 251 receptors. This effect is selective for angiotensin AT1 receptors as endothelin-1-induced, ETA 252 receptor-mediated vasoconstriction is not inhibited, and no unspecific effects on 253 depolarization-induced vasoconstriction are shown. 254
We have previously reported that the low molecular weight LF hydroysate included in 255 this study (LFH<3 kDa) shows antihypertensive effects in SHRs. Single-dose LFH<3 kDa induces 256 acute blood pressure reduction in SHRs, 12 and long-term intake attenuates progression of 257 hypertension. 13 LFH<3 kDa inhibits both in vitro ACE activity 12 and ACE-dependent angiotensin 258 I-induced vasoconstriction. 18 The ACE inhibitory effect of LFH<3 kDa has been confirmed as an 259 in vivo mechanism for the antihypertensive effect. 13 The present results point to inhibition of 260 angiotensin II-induced vasocontriction as a potential mechanism also contributing along with 261 ACE inhibition to the antihypertensive effect of the hydrolysate. We have also previously 262
shown that individual peptides embedded in different regions of the LF sequence, either 263 derived from the lactoferricin B domain (LfcinB) or identified in LFH<3 kDa, are ACE inhibitors 264 and have antihypertensive effects when acutely administered to SHRs. 9,10,12 The present study 265 shows that LfcinB20-25 also has a slight inhibitory effect on angiotensin II-induced The inhibitory effects of food-derived antihypertensive peptides on angiotensin II-288 induced vasoconstriction have not been extensively studied, and when done no inhibition has 289 been found. Others have reported the lack of effect of the milk-derived tripeptide IPP 24 and 290 the sardine muscle-derived dipeptide VY 25 on angiotensin II-induced vasoconstriction. In a 291 previous study with rationally designed heptapeptides, we found that the ACE inhibitor 292 13 antihypertensive heptapeptide PACEI50 (RKWHFLW) did not modify angiotensin II-induced 293 vasoconstriction. 26 With regard to LF-derived peptides, the crude LF pepsin hydrolysate before 294 ultrafiltration (LFH) did not inhibit angiotensin II-induced vasoconstriction, did not modify 295 blood pressure in SHRs, and showed much less inhibitory potency on ACE than LFH<3 kDa, 11,12 296 thus indicating that the antihypertensive effects of the LF hydrolysate are due to the bioactive 297 properties of its low molecular weight peptides like LIWKL and RPYL. 298
To the best of our knowledge, the present study for the first time shows the ability of 299 antihypertensive bioactive peptides to inhibit angiotensin II-induced vasoconstriction by an 300 angiotensin AT1 receptor blocking mechanism. With regard to non peptide substances, 301 inhibition of angiotensin II-induced vasoconstriction has been reported to underlie the 302 antihypertensive effects of compounds like nitro-oleic acid, a NO-derived fatty acid, 27 and 303 especially plant extracts used in folk medicine. [28] [29] [30] [31] [32] Moreover, proanthocyanidins and alkaloids 304 from some plant extracts are angiotensin AT1 receptor binding compounds. [33] [34] [35] On the other 305 hand, inhibitory effects on renin activity, the rate limiting enzyme upstream the RAS, 36 have 306 been reported for hemp seed protein hydrolysates, 37 flaxseed protein hydrolysate fractions 38 307 and peptides from pea protein hydrolysates, 39 as well as for peptides from a protein 308 hydrolysate of the macroalga Palmaria palmate. 40 In most of these cases, inhibitory effects 309 were observed on both renin and ACE activities. 37-39 Therefore, bioactive peptides with 310 antihypertensive potential can be multifunctional peptides inhibiting more than one of the RAS 311 steps: generation of angiotensin I from angiotensinogen by renin, generation of vasoactive 312 angiotensin II from angiotensin I by ACE, or activation of the AT1 receptor by angiotensin II. 36 313
The endothelin system, similar to the RAS, is another peptidic system with an 314 increasingly recognized role in blood pressure regulation and hypertension pathophysiology. 41 315
Of particular relevance in the cardiovascular system, endothelin-1 has powerful 316 vasoconstrictor and pressor properties. The gene product preproendothelin-1 is cleaved by a 317 furin-like endopeptidase to form a biologically inactive intermediate termed big endothelin-1. 318 14 Next, big ET-1 is cleaved by an endothelin-converting enzyme (ECE) to form endothelin-1, 319 which binds to vascular ETA receptors to induce vasoconstriction. 42 Both AT1 and ETA receptors 320 belong to the class 1 of G protein-coupled receptors, 43 and dual action AT1 and ETA receptor 321
antagonists reduce blood pressure in experimental hypertension. 44 Moreover, angiotensin AT1 322 receptor binding alkaloids from the root of Bocconia frutescens also show weaker binding to 323 endothelin ETA receptors. 34 Our results show that neither LFH<3 kDa nor RPYL, the peptide 324 with the highest inhibitory effect on angiotensin II-induced vasoconstriction, modified the 325 vasoconstriction induced by endothelin-1, thus supporting the selective effects of LF-derived 326 peptides on the AT1 receptor. In a previous study, we reported that LfcinB-derived peptides 327 
